Gene: MLLT3

4300
AF9|YEATS3
MLLT3, super elongation complex subunit
protein-coding
9p21.3
Ensembl:ENSG00000171843 MIM:159558 Vega:OTTHUMG00000019650 UniprotKB:P42568
NC_000009.12
PubMed|SNP Mapped
2   ANCO-SNPs
ND
1   
NA (AD)  NA (ND)   (Frontal_Cortex)
7.777e-1 (AD)  1.958e-2 (ND)

ANCO-SNPs

SNP ID Position Alleles Trait Variation Type
rs12380857chr9:20578042 (GRCh38.p7)T>Cnicotine dependenceSNV(Single Nucleotide Variation)
rs7868755chr9:20551929 (GRCh38.p7)C>Tnicotine dependenceSNV(Single Nucleotide Variation)

DNA Methylation

There is no related methylation information for this gene.

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
TBPL10.916
RHOT10.916
FAM117B0.911
DCAF100.907
RBBP50.902
MCU0.899
GOPC0.894
UBE2W0.894
FBXO280.89
FGFR1OP20.89

Top 10 negatively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
OR4F5-0.522
OR4F29-0.481
FZD10-0.42
TFPI2-0.397
KLRB1-0.391
CSAG1-0.371
KLRF1-0.367
RAI14-0.356
CD248-0.352
ASB4-0.351

Drugs/Compounds

    There is no DrugBank record for this gene !

ID Drug Name Action PubMed
C5486512-(1'H-indolo-3'-carbonyl)thiazole-4-carboxylic acid methyl ester2-(1'H-indolo-3'-carbonyl)thiazole-4-carboxylic acid methyl ester results in increased expression of MLLT3 mRNA19933214
C1111182',3,3',4',5-pentachloro-4-hydroxybiphenyl"2',3,3',4',5-pentachloro-4-hydroxybiphenyl results in decreased expression of MLLT3 mRNA"19114083
C0179063-dinitrobenzene3-dinitrobenzene results in increased expression of MLLT3 mRNA21983209
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MLLT3 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MLLT3 mRNA"27188386
D000082AcetaminophenAcetaminophen affects the expression of MLLT3 mRNA25458485
D000082AcetaminophenAcetaminophen results in decreased expression of MLLT3 mRNA26690555
D000082AcetaminophenAcetaminophen affects the expression of MLLT3 mRNA17562736
D016604Aflatoxin B1Aflatoxin B1 results in increased expression of MLLT3 mRNA27153756
D000517alpha-Chlorohydrinalpha-Chlorohydrin results in increased expression of MLLT3 mRNA28522335
D000643Ammonium ChlorideAmmonium Chloride affects the expression of MLLT3 mRNA16483693
D018501Antirheumatic AgentsAntirheumatic Agents results in increased expression of MLLT3 mRNA24449571
D001280AtrazineAtrazine results in increased expression of MLLT3 mRNA22378314
D001564Benzo(a)pyreneBenzo(a)pyrene results in decreased expression of MLLT3 mRNA20106945|2163298
D001564Benzo(a)pyreneBenzo(a)pyrene results in decreased expression of MLLT3 mRNA21715664
D0151237,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide"7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide results in decreased expression of MLLT3 mRNA"19150397
D004958EstradiolEstradiol affects the expression of MLLT3 mRNA22574217
D004958Estradiol[bisphenol A co-treated with Estradiol] results in increased expression of MLLT3 mRNA26496021
C006780bisphenol Abisphenol A affects the expression of MLLT3 mRNA21786754
C006780bisphenol Abisphenol A affects the expression of MLLT3 mRNA21786754
C006780bisphenol Abisphenol A affects the expression of MLLT3 mRNA25181051
C006780bisphenol A[bisphenol A co-treated with Estradiol] results in increased expression of MLLT3 mRNA26496021
C006780bisphenol Abisphenol A results in increased methylation of MLLT3 gene28505145
C037123cadmium sulfatecadmium sulfate results in decreased expression of MLLT3 mRNA19274763
D002110CaffeineCaffeine results in increased expression of MLLT3 mRNA23774253
D002220CarbamazepineCarbamazepine results in increased expression of MLLT3 mRNA23774253
D002220CarbamazepineCarbamazepine affects the expression of MLLT3 mRNA25979313
D002737ChloropreneChloroprene results in increased expression of MLLT3 mRNA23125180
D002794Choline[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased expression of MLLT3 mRNA20938992
D016572CyclosporineCyclosporine results in decreased expression of MLLT3 mRNA20106945|2556210
D016572CyclosporineCyclosporine results in decreased expression of MLLT3 mRNA19770486
C000944dicrotophosdicrotophos results in decreased expression of MLLT3 mRNA28302478
D004052DiethylnitrosamineDiethylnitrosamine results in increased expression of MLLT3 mRNA24535843
D004317DoxorubicinDoxorubicin results in decreased expression of MLLT3 mRNA16404146
C024565ethylene dichlorideethylene dichloride results in increased expression of MLLT3 mRNA28189721
D005419FlavonoidsFlavonoids results in decreased expression of MLLT3 mRNA18035473
D005492Folic Acid[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased expression of MLLT3 mRNA20938992
D017313FenretinideFenretinide results in decreased expression of MLLT3 mRNA28973697
D007649KetamineKetamine results in decreased expression of MLLT3 mRNA20080153
C008261lead acetate[lead acetate co-treated with zinc protoporphyrin] results in increased expression of MLLT3 mRNA22839698
C008261lead acetatelead acetate results in increased expression of MLLT3 mRNA21829687
C045463leflunomideleflunomide results in decreased expression of MLLT3 mRNA19751817
D008558MelphalanMelphalan results in decreased expression of MLLT3 mRNA22363485
D008715Methionine[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased expression of MLLT3 mRNA20938992
C005219methyl cellosolvemethyl cellosolve results in increased expression of MLLT3 mRNA21061450
C004925methylmercuric chloridemethylmercuric chloride results in decreased expression of MLLT3 mRNA28001369
D008741Methyl MethanesulfonateMethyl Methanesulfonate results in decreased expression of MLLT3 mRNA23649840
D037742Nanotubes, Carbon"Nanotubes, Carbon results in decreased expression of MLLT3 mRNA"25554681
C029938nickel sulfatenickel sulfate results in decreased expression of MLLT3 mRNA22714537
C030110oxaliplatin[oxaliplatin co-treated with Topotecan] results in decreased expression of MLLT3 mRNA25729387
D010795Phthalic AcidsPhthalic Acids results in increased expression of MLLT3 mRNA21061450
D011374ProgesteroneProgesterone results in increased expression of MLLT3 mRNA23012394
D011441PropylthiouracilPropylthiouracil results in increased expression of MLLT3 mRNA24780913
D011794QuercetinQuercetin results in decreased expression of MLLT3 mRNA21632981
D012834SilverSilver results in decreased expression of MLLT3 mRNA27131904
D013739TestosteroneTestosterone results in decreased expression of MLLT3 mRNA20403060
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin affects the expression of MLLT3 mRNA22574217
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin affects the expression of MLLT3 mRNA21570461
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin results in increased expression of MLLT3 mRNA19933214
D019772Topotecan[oxaliplatin co-treated with Topotecan] results in decreased expression of MLLT3 mRNA25729387
D019772TopotecanTopotecan results in decreased expression of MLLT3 mRNA25729387
D014212TretinoinTretinoin results in decreased expression of MLLT3 mRNA23724009
D014241TrichloroethyleneTrichloroethylene results in increased methylation of MLLT3 gene27618143
C012589trichostatin Atrichostatin A affects the expression of MLLT3 mRNA28542535
C012589trichostatin Atrichostatin A results in increased expression of MLLT3 mRNA24935251
D014520UrethaneUrethane results in increased expression of MLLT3 mRNA28818685
D014635Valproic Acid"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MLLT3 mRNA"27188386
D014635Valproic AcidValproic Acid affects the expression of MLLT3 mRNA25979313|2607246
D014635Valproic AcidValproic Acid results in increased expression of MLLT3 mRNA19101580|2317975
D014635Valproic AcidValproic Acid affects the expression of MLLT3 mRNA17292431|2607246
D001335Vehicle EmissionsVehicle Emissions results in decreased methylation of MLLT3 gene25560391
C025643vinclozolinvinclozolin results in decreased expression of MLLT3 mRNA20566332
D014750VincristineVincristine results in increased expression of MLLT3 mRNA23649840
C017803zinc protoporphyrin[lead acetate co-treated with zinc protoporphyrin] results in increased expression of MLLT3 mRNA22839698

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO:0000981RNA polymerase II transcription factor activity, sequence-specific DNA binding-ISM19274049  
GO:0003682chromatin binding-IDA25417107  27105114  
GO:0005515protein binding-IPI16189514  20153263  20203130  21729782  23145062  23260655  
26496610  
GO:0042393histone binding-IDA27105114  27545619  
GO:0070577lysine-acetylated histone binding-IDA25417107  
GO:0140030modification-dependent protein binding-IDA27105114  27545619  
GO ID GO Term Qualifier Evidence PubMed
GO:0006357regulation of transcription by RNA polymerase II-IEA-  
GO:0006366transcription by RNA polymerase II-TAS-  
GO:0006368transcription elongation from RNA polymerase II promoter-TAS-  
GO:0007379segment specification-IEA-  
GO:0009952anterior/posterior pattern specification-IEA-  
GO:0045893positive regulation of transcription, DNA-templated-IDA25417107  27105114  
GO:0090090negative regulation of canonical Wnt signaling pathway-IDA19591803  
GO:0090090negative regulation of canonical Wnt signaling pathway-IGI19591803  
GO:2000096positive regulation of Wnt signaling pathway, planar cell polarity pathway-IGI19591803  
GO ID GO Term Qualifier Evidence PubMed
GO:0005634nucleus-TAS8506309  
GO:0005654nucleoplasm-TAS-  
GO:0005694chromosome-IEA-  
GO:0008023transcription elongation factor complex-IDA22195968  25417107  27105114  
GO:0070062extracellular exosome-HDA19056867  
KEGG ID KEGG Term
Reactome ID Reactome Term Evidence
R-HSA-112382Formation of RNA Pol II elongation complex TAS
R-HSA-674695RNA Polymerase II Pre-transcription EventsTAS
R-HSA-73857RNA Polymerase II TranscriptionTAS
R-HSA-74160Gene expression (Transcription)TAS
R-HSA-75955RNA Polymerase II Transcription ElongationTAS

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal
21618603Evidence for gene-environment interaction in a genome wide study of nonsyndromic cleft palate. (2011 Sep)Beaty THGenet Epidemiol